PRRT2 and lung cancer: The immunoblotting analysis revealed that Wnt5a could increase the expression of phosphorylated PCK (phos-PKC), CaMKII, and NFκB in the Wnt/PKC signaling cascade, and PKC inhibitor GF109203X decreased the expression of phos-PKC, CaMKII, and NFκB in both A549 (Figures 6(a) and 6(b)) and A549/DDP lung cancer cells (Figures 6(c) and 6(d)).